Heo Mi Jeong, Cheon Inyoung, Kim Kang Ho
Department of Anesthesiology, Critical Care and Pain Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA; Center for Perioperative Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Department of Anesthesiology, Critical Care and Pain Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA; Center for Perioperative Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA; Department of Molecular Medicine and Inflammation-Cancer Microenvironment Research Center, College of Medicine, Ewha Womans University, Seoul 07804, Republic of Korea.
Trends Endocrinol Metab. 2025 Jun;36(6):507-510. doi: 10.1016/j.tem.2024.11.015. Epub 2024 Dec 18.
Orosomucoids (ORMs) have historically been considered as carriers involved in drug and lipid delivery. However, recent studies indicate ORM2 as a hepatokine involved in metabolic regulation. Here, we highlight the functions of ORM2 in controlling metabolic health and disease, focusing on its newly discovered regulatory mechanisms.
历史上，血清类黏蛋白（ORMs）一直被认为是参与药物和脂质递送的载体。然而，最近的研究表明，ORM2是一种参与代谢调节的肝源性激素。在此，我们重点介绍ORM2在控制代谢健康和疾病方面的功能，着重关注其新发现的调节机制。
